Grin and Bayer it
23 March 2006
The German conglomerate is acting as Schering’s white knight. Its bid of E86 per share trounces Merck’s hostile offer of E77. Merck will be hard pressed to beat this offer. Bayer has greater synergies with Schering than Merck does.